Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
4(50%)
Results Posted
50%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_4
1
13%
Ph phase_1
3
38%
Ph not_applicable
1
13%
Ph phase_2
3
38%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Active, not recruiting2
Recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 41 (12.5%)
N/A1 (12.5%)

Trials by Status

not_yet_recruiting113%
terminated113%
completed225%
active_not_recruiting225%
recruiting225%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
DEVICE
Total Trials
8